Idezar

HTN. Treatment of diabetic nephropathy w/ an increased serum creatinine & proteinuria (>300 mg/day) in patients w/ type 2 diabetes & HTN. Decreases the progression of nephropathy as measured by the occurrence of doubling serum creatinine or ESRD (need for dialysis or renal transplantation).

HTN Initially 150 mg once daily. Titrate dose to 300 mg once daily in patients requiring further reduction in BP. Diabetic nephropathy Initially 150 mg once daily. Maintenance: 300 mg once daily. Elderly Initially 75 mg once daily. Vol- & salt-depleted patient (eg, treated vigorously w/ diuretics or on hemodialysis) Initially 75 mg once daily.

May be taken with or without food.

Hypersensitivity. Pregnancy (2nd & 3rd trimesters).

Risk of fetal/neonatal morbidity & mortality. Discontinue as soon as pregnancy is detected. Hypotension in vol- or salt-depleted patients, hyperkalemia (especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease &/or heart failure). Patients w/ aortic & mitral valve stenosis, obstructive hypertrophic cardiomyopathy; primary aldosteronism; patients whose vascular tone and renal function depend predominantly on the activity of this system (eg, severe CHF or underlying renal disease including renal artery stenosis); ischemic cardiopathy/CV disease (excessive hypotension will result in MI or stroke). Periodic monitoring of K & creatinine serum levels in patients w/ impaired renal function. Renal impairment & kidney transplant. Black patients. Pregnancy (1st trimester) & lactation. Childn <6 yr. Elderly.

Chills, edema, facial edema, fatigue, fever, flu, upper extremity edema; angina pectoris, arrhythmic/conduction disorder, cardiac murmur, cardio-resp arrest, CVA, chest pain, flushing, heart failure, HTN, hypertensive crisis, hypotension, MI, orthostatic dizziness, orthostatic hypotension, sinus abnormality, tachycardia, transient ischemic attack; gout; hyperkalemia; libido change; sexual dysfunction; elevated LFTs, BUN & serum creatinine; decreased Hb; abdominal distention, abdominal pain, constipation, diarrhea, dysgeusia, dyspepsia, flatulence, gastroenteritis, heartburn, hepatitis, jaundice, nausea, oral lesion, vomiting; abnormal urination, impaired renal function including cases of renal failure, prostate disorder, UTI; neutropenia; arthralgia, arthritis, bursitis, extremity swelling, joint stiffness, muscle ache, muscle cramp, muscle weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia; anxiety, depression, dizziness, emotional disturbance, headache, nervousness, numbness, paresthesia, sleep disturbance, somnolence, syncope, tremor, vertigo.

May increase serum K w/ K-sparing diuretics, K supplements/salt substitutes. Reversible increase in serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs ie, selective COX-2 inhibitors, aspirin >3 g/day. Increased hypotensive effects w/ other antihypertensives eg, β-blockers, long-acting Ca channel blockers & thiazide diuretics.

Angiotensin II Antagonists

C09CA04 - irbesartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx